Cronos Group Inc.

NasdaqGM:CRON Stock Report

Market Cap: US$793.2m

Cronos Group Valuation

Is CRON undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRON when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRON ($2.08) is trading above our estimate of fair value ($0.03)

Significantly Below Fair Value: CRON is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRON?

Key metric: As CRON is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CRON. This is calculated by dividing CRON's market cap by their current revenue.
What is CRON's PS Ratio?
PS Ratio7.1x
SalesUS$111.23m
Market CapUS$793.17m

Price to Sales Ratio vs Peers

How does CRON's PS Ratio compare to its peers?

The above table shows the PS ratio for CRON vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average18.4x
PCRX Pacira BioSciences
1.2x0.6%US$810.3m
LQDA Liquidia
57.7x59.6%US$901.4m
EYPT EyePoint Pharmaceuticals
13.7x44.8%US$627.9m
PAHC Phibro Animal Health
0.9x2.7%US$961.6m
CRON Cronos Group
7.1x4.9%US$1.1b

Price-To-Sales vs Peers: CRON is good value based on its Price-To-Sales Ratio (7.1x) compared to the peer average (18.4x).

Price to Sales Ratio vs Industry

How does CRON's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

73 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.94b
PRGO Perrigo
0.9x3.4%US$3.83b
BHC Bausch Health Companies
0.3x1.5%US$2.93b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
CRON 7.1xIndustry Avg. 2.8xNo. of Companies73PS048121620+
73 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CRON is expensive based on its Price-To-Sales Ratio (7.1x) compared to the US Pharmaceuticals industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is CRON's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRON PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.1x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: CRON is expensive based on its Price-To-Sales Ratio (7.1x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRON forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.08
US$2.46
+18.1%
25.3%US$3.57US$1.97n/a6
Nov ’25US$2.16
US$2.49
+15.5%
25.3%US$3.63US$2.00n/a6
Oct ’25US$2.13
US$2.58
+21.3%
23.7%US$3.68US$2.06n/a6
Sep ’25US$2.26
US$2.57
+13.6%
21.4%US$3.64US$2.05n/a7
Aug ’25US$2.35
US$2.64
+12.3%
20.6%US$3.65US$2.06n/a7
Jul ’25US$2.30
US$2.64
+14.8%
20.6%US$3.65US$2.06n/a7
Jun ’25US$2.59
US$2.75
+6.1%
19.4%US$3.67US$2.06n/a7
May ’25US$2.71
US$2.61
-3.8%
20.0%US$3.66US$2.05n/a7
Apr ’25US$2.64
US$2.55
-3.4%
22.7%US$3.68US$1.94n/a7
Mar ’25US$2.02
US$2.50
+23.8%
24.4%US$3.69US$1.95n/a7
Feb ’25US$2.16
US$2.60
+20.6%
22.6%US$3.73US$1.97n/a7
Jan ’25US$2.09
US$2.57
+23.2%
22.9%US$3.79US$2.00n/a8
Dec ’24US$2.10
US$2.47
+17.4%
23.7%US$3.65US$1.80n/a8
Nov ’24US$1.74
US$2.42
+39.2%
26.1%US$3.65US$1.54US$2.168
Oct ’24US$2.00
US$2.52
+25.9%
25.0%US$3.70US$1.56US$2.139
Sep ’24US$1.97
US$2.45
+24.2%
24.7%US$3.69US$1.56US$2.269
Aug ’24US$1.91
US$2.56
+34.2%
25.3%US$3.77US$1.59US$2.359
Jul ’24US$1.97
US$2.56
+30.1%
25.3%US$3.77US$1.59US$2.309
Jun ’24US$1.74
US$2.55
+46.5%
23.8%US$3.68US$1.55US$2.599
May ’24US$1.88
US$3.09
+64.4%
31.7%US$5.23US$2.14US$2.719
Apr ’24US$1.94
US$3.24
+66.9%
28.0%US$5.15US$2.10US$2.649
Mar ’24US$2.12
US$3.24
+52.8%
28.0%US$5.15US$2.10US$2.029
Feb ’24US$2.51
US$3.86
+53.6%
37.7%US$7.53US$2.54US$2.1610
Jan ’24US$2.54
US$3.84
+51.1%
36.5%US$7.39US$2.50US$2.0910
Dec ’23US$3.26
US$3.84
+17.7%
36.5%US$7.39US$2.50US$2.1010
Nov ’23US$3.23
US$4.17
+29.0%
44.8%US$8.07US$2.20US$1.7410

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

1.3%

1Y

15.1%